Stevens Johnson Syndrome and Toxic Epidermal Necrolysis Updates on Management
Main Article Content
Abstract
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are dermatologic emergencies characterized by extensive epidermal necrolysis and sloughing. The incidence rates vary depending on location, with the UK experiencing an annual incidence of 5.76 cases per million individuals from 1995 to 2013. Females are more frequently afflicted than males, with mortality rates ranging from 4.8-9% to 14.8-48%.
Nonpharmacologic treatment for SJS/TEN patients includes supportive care, fluid and electrolyte management, infection control, and wound care. The most critical component is the identification and cessation of the causative substance. Management of fluid, electrolytes, and nutrition is crucial for SJS/TEN patients, as they have lower fluid requirements than burn patients.
Prophylactic antibiotics do not enhance outcomes, but infection prevention requires appropriate wound care and antiseptic handling. The role of surgical debridement has been a topic of controversy, and the decision to pursue this treatment option depends on the location of care. Anti-shear therapy, which involves aspiration of blister fluid and preservation of denuded epidermis, has been shown to be effective in reducing mortality rates.
Pharmacologic treatment for SJS/TEN has been the subject of few prospective studies due to the disease's rarity. Various treatment regimens involving corticosteroids, IVIg, cyclosporine, and TNF-alpha inhibitors have been reported, but it is challenging to determine whether the disease's remission was due to a specific treatment or the natural course of the disease.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Frantz, R., Huang, S., Are, A., & Motaparthi, K. (2021). Stevens–Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management. Medicina, 57(9), 895.
II. Owen, C. E., & Jones, J. M. (2021). Recognition and management of severe cutaneous adverse drug reactions (including drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis). Medical Clinics, 105(4), 577-597.
III. Jaller, J. A., McLellan, B. N., & Balagula, Y. (2020). Wound management in Stevens-Johnson Syndrome and toxic epidermal necrolysis. Current Dermatology Reports, 9, 58-72.
IV. Garg, V. K., Buttar, H. S., Bhat, S. A., Ainur, N., Priya, T., Kashyap, D., & Tuli, H. S. (2023). Stevens-johnson Syndrome and Toxic Epidermal Necrolysis: An Overview of Diagnosis, Therapy Options and Prognosis of Patients. Recent Advances in Inflammation & Allergy Drug Discovery, 17(2), 110-120.
V. Abulatan, I. T., Ben-David, S. G., Morales-Colon, L. A., Beason, E., & Fakoya, A. O. (2023). A compilation of drug etiologies of stevens-johnson syndrome and toxic epidermal necrolysis. Cureus, 15(11).
VI. Charlton, O. A., Harris, V., Phan, K., Mewton, E., Jackson, C., & Cooper, A. (2020). Toxic epidermal necrolysis and Steven–Johnson syndrome: a comprehensive review. Advances in wound care, 9(7), 426-439.
VII. Rahesh, J., Al-Sukhni, L., & Griswold, J. (2022). Stevens-Johnson syndrome/toxic epidermal necrolysis management in the burn intensive care unit: A case series. The Southwest Respiratory and Critical Care Chronicles, 10(44), 40-44.
VIII. Thong, B. Y. H. (2023). Drug-induced Stevens Johnson syndrome and toxic epidermal necrolysis: Interpreting the systematic reviews on immunomodulatory therapies. Asia Pacific Allergy, 13(2), 72-76.